Susquehanna International Group Ltd. purchased a new stake in Qiagen NV (NYSE:QGEN) during the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor purchased 17,430 shares of the company’s stock, valued at approximately $600,000. Qiagen makes up approximately 0.5% of Susquehanna International Group Ltd.’s portfolio, making the stock its 24th largest holding.
Several other hedge funds have also added to or reduced their stakes in QGEN. Morgan Stanley boosted its stake in shares of Qiagen by 16.3% in the 3rd quarter. Morgan Stanley now owns 1,468,052 shares of the company’s stock valued at $55,611,000 after purchasing an additional 205,698 shares in the last quarter. Vanguard Group Inc boosted its stake in shares of Qiagen by 2.0% in the 3rd quarter. Vanguard Group Inc now owns 6,627,163 shares of the company’s stock valued at $251,037,000 after purchasing an additional 128,125 shares in the last quarter. First Bank & Trust boosted its stake in shares of Qiagen by 12.7% in the 4th quarter. First Bank & Trust now owns 5,552 shares of the company’s stock valued at $191,000 after purchasing an additional 624 shares in the last quarter. Frontier Capital Management Co. LLC boosted its stake in shares of Qiagen by 1.3% in the 4th quarter. Frontier Capital Management Co. LLC now owns 2,653,307 shares of the company’s stock valued at $91,406,000 after purchasing an additional 34,078 shares in the last quarter. Finally, Oppenheimer Asset Management Inc. acquired a new stake in shares of Qiagen in the 4th quarter valued at approximately $118,000. Institutional investors and hedge funds own 64.00% of the company’s stock.
NYSE QGEN traded up $0.01 during trading hours on Monday, reaching $39.85. The company’s stock had a trading volume of 11,727 shares, compared to its average volume of 1,408,189. The firm has a market cap of $8.98 billion, a PE ratio of 29.74, a price-to-earnings-growth ratio of 2.45 and a beta of 0.91. Qiagen NV has a 52 week low of $31.10 and a 52 week high of $40.19. The company has a debt-to-equity ratio of 0.63, a current ratio of 2.22 and a quick ratio of 2.05.
QGEN has been the topic of a number of research analyst reports. UBS Group initiated coverage on shares of Qiagen in a research note on Friday. They issued a “neutral” rating and a $42.00 price target on the stock. Deutsche Bank restated a “buy” rating on shares of Qiagen in a research note on Tuesday, January 29th. Finally, Jefferies Financial Group restated a “neutral” rating on shares of Qiagen in a research note on Monday, January 14th. Eight analysts have rated the stock with a hold rating and six have issued a buy rating to the company. Qiagen has a consensus rating of “Hold” and an average price target of $41.17.
ILLEGAL ACTIVITY WARNING: “Susquehanna International Group Ltd. Purchases Shares of 17,430 Qiagen NV (QGEN)” was posted by Markets Daily and is the property of of Markets Daily. If you are reading this article on another domain, it was illegally copied and republished in violation of U.S. & international copyright laws. The legal version of this article can be accessed at https://www.themarketsdaily.com/2019/03/18/susquehanna-international-group-ltd-purchases-shares-of-17430-qiagen-nv-qgen.html.
QIAGEN N.V. provides sample to insight solutions that transform biological materials into molecular insights worldwide. The company offers sample technologies for plasmid deoxyribonucleic acid (DNA) purification, ribonucleic acid purification and stabilization, genomic and viral nucleic acid purification, DNA cleanup after polymerase chain reaction (PCR) and sequencing, target enrichment, and library preparation for sequencing applications; and assay technology solutions.
Read More: Why is cost of goods sold important?
Receive News & Ratings for Qiagen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Qiagen and related companies with MarketBeat.com's FREE daily email newsletter.